Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ipsen Hungry For More Deals After Swallowing Epizyme

$247m Upfront For Lymphoma Drug Tazverik

Jun 27 2022

• By Kevin Grogan

Ipsen — • Source: Alamy

Related Content

Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio

Jun 08 2022

Ipsen Gives Genfit Liver Drug New Lease Of Life

Dec 17 2021

Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders

Aug 03 2021

Ipsen To Exit Consumer Health And Focus On Specialty Pharma

Feb 11 2022

Related Companies

Ipsen SA

Epizyme, Inc.

Roche Holding AG

BAKX Therapeutics Inc.

Exicure, Inc.

Genfit SA

Mayoly-Spindler SAS

Additional Topics

M & A Strategy Commercial Companies Deals Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.